Inhibitors of transcription factor NF-kappaB

a transcription factor and inhibitor technology, applied in the field of salicylanilide inhibitors of transcription factor nfb, can solve problems such as organ destruction

Inactive Publication Date: 2006-02-16
SMITHKLINE BECKMAN CORP
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015] In still another aspect, this invention provides a method of treating disease

Problems solved by technology

Such mediators are known to play a role in the recruitment of leukocytes at sites of inflammation a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of transcription factor NF-kappaB
  • Inhibitors of transcription factor NF-kappaB
  • Inhibitors of transcription factor NF-kappaB

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of N-(4-Acetylphenyl)-2-hydroxy-5-iodocarboxamide

[0099] A solution of iodosalicylic acid (1.9 g, 7.4 mmol) and 4-aminoacetophenone (0.97 g, 7.4 mmol) in chlorobenzene (40 mL) was treated with PCl3 (0.323 mL, 3.7 mmol). The solution was heated at reflux under an argon atmosphere. After 2 h. the solution was filtered hot and the filtrate was left standing at RT. After 18 h solution was filtered and the solid was recrystallized from MeOH to give the title compound (0.095 g, 5% yield): 1H NMR (400 MHz, DMSO-d6) δ 2.5-2.6 (s, 3H), 6.8-8.2 (m, 7H), 10.1-10.2 (s, 1H).

example 2

Preparation of N-(2,4-Difluorophenyl)-2-hydroxy-5-nitrophenylcarboxamide

[0100] A solution of 5-nitrosalicylic acid (1.4 g, 7.7 mmol) and 2,4difluoroaniline (0.8 mL, 7.7 mmol) in chlorobenzene (40 mL) was treated with PCl3 (0.338 mL, 3.8 mmol). The solution was heated at reflux under an argon atmosphere. After 2 h. the solution was filtered hot and the filtrate was left standing at RT. After 18 h the solution was filtered and the solid was recrystallized from MeOH to give the title compound (0.733 g, 35% yield): 1H NMR (400 MHz, DMSO-d6) δ 2.5-2.6 (s, 3H), 7.1-8.9 (m, 6H), 10.6-10.7 (s, 1H)

example 3

Preparation of N-(2,4-Difluorophenyl)-2-hydroxy-5-iodophenylcarboxamide

a) 5-Iodosalicylic acidchloride

[0101] 5-Iodosalicylic acid (2.0 g, 7.58 mmol) in toluene was treated with SOCl2 (1.66 mL, 22.7 mmol) and catalytic DMF at reflux for 1 h. The reaction mixture was evaporated to dryness and the acid chloride used in the next step without purification.

b) 2,4-Difluorophenyl)-2-hydroxy-5-iodophenylcarboxamide

[0102] The compound of Example 3(a) (3.79 mmol) and 2,4-difluoroaniline (380 uL, 3.79 mmol) in toluene was heated at reflux for 24 h. The reaction mixture was evaporated, the residue washed with ether and the solid residue recrystallized from MeOH to give 159 mg of N-(2,4-difluorophenyl)-2-hydroxy-5-iodophenylcarboxamide. ES MS (M+H)− m / e 373.7.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

Description

FIELD OF THE INVENTION [0001] This invention relates in general to salicylanilide inhibitors of transcription factor NF-κB. Such compounds are particularly useful for treating diseases in which activation of NF-κB is implicated. More specifically, these compounds inhibit IκB phosphorylation and subsequent degradation. Such compounds are useful in the treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins disease; and certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia. BACKGROUND OF THE INVENTION [0002] Recent advances in scientific understanding of the mediators involved in acute and chronic inflammatory diseases and cancer have le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/165A61P1/00A61K31/167A61P9/00A61P9/10A61P11/06A61P17/00A61P17/06A61P19/02A61P19/10A61P25/28A61P29/00A61P31/18A61P35/00A61P37/02A61P37/04A61P37/06A61P43/00C07C235/64
CPCC07C235/64A61K31/165A61P1/00A61P11/06A61P17/00A61P17/06A61P19/02A61P19/10A61P25/28A61P29/00A61P31/18A61P35/00A61P37/02A61P37/04A61P37/06A61P43/00A61P9/00A61P9/10A61K31/16
Inventor CALLAHAN, JAMES F.CHABOT-FLETCHER, MARIE C.
Owner SMITHKLINE BECKMAN CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap